Login to Your Account

DUBLIN – Glionova AB, a Swedish start-up exploiting a novel mechanism of action in cancer, raised SEK42 million (US$5.7 million) in a series A round to take forward its lead drug, GLN-1001, which is in development for glioblastoma.
Triphase Accelerator Corp., a tiny drug developer with big backing from a Celgene Corp. deal, is pushing to bring economic rationality to the long haul between investigational new drug application filings and phase II proof of concept.
Rigontec GmbH, a spinout from the University of Bonn in Germany, took in €9.45 million (US$12 million) in a first closing of a series A round to take forward an RNA-based approach to immunotherapy, based on activating retinoic acid inducible protein I (RIG-I), a pathogen-associated molecular pattern that recognizes certain forms of viral RNA.
More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: